Ray Dalio's TEVA Position Overview
Ray Dalio (via Bridgewater Associates, Lp) currently holds 1.13 M shares of Teva Pharmaceutical Industries Limited (TEVA) worth $33.99 M, representing 0.15% of the portfolio. First purchased in 2015-Q4, this long-term strategic position has been held for 32 quarters.
Based on 13F filings, Ray Dalio has maintained a strategic position in TEVA, demonstrating sustained confidence in this investment. Largest addition occurred in Q3 2025, adding 864,782 shares. Largest reduction occurred in Q4 2022, reducing 134,841 shares.
Analysis based on 13F filings available since 2013 Q2
Ray Dalio's Teva Pharmaceutical Industries Limited (TEVA) Holding Value Over Time
Track share changes against reported price movement
Quarterly Teva Pharmaceutical Industries Limited (TEVA) Trades by Ray Dalio
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q1 2026 | +374,313 | Add 49.64% | 1.13 M | $30.12 |
| Q4 2025 | -110,689 | Reduce 12.80% | 754,093 | $31.21 |
| Q3 2025 | +864,782 | New Buy | 864,782 | $20.20 |
| Q1 2025 | -9,393 | Sold Out | 0 | $0.00 |
| Q4 2024 | -13,829 | Reduce 59.55% | 9,393 | $22.04 |
| Q3 2024 | +1,144 | Add 5.18% | 23,222 | $18.02 |
| Q2 2024 | -24,583 | Reduce 52.68% | 22,078 | $16.25 |
| Q1 2024 | -26,413 | Reduce 36.15% | 46,661 | $14.11 |
| Q4 2023 | -121,451 | Reduce 62.43% | 73,074 | $10.44 |
| Q3 2023 | -37,985 | Reduce 16.34% | 194,525 | $10.20 |
| Q2 2023 | -10,137 | Reduce 4.18% | 232,510 | $7.53 |
| Q1 2023 | -66,770 | Reduce 21.58% | 242,647 | $8.85 |
| Q4 2022 | -134,841 | Reduce 30.35% | 309,417 | $9.12 |
| Q3 2022 | -40,785 | Reduce 8.41% | 444,258 | $8.07 |
| Q2 2022 | -56,471 | Reduce 10.43% | 485,043 | $7.52 |
| Q1 2022 | +21,895 | Add 4.21% | 541,514 | $9.39 |
| Q4 2021 | +244,402 | Add 88.80% | 519,619 | $8.01 |
| Q3 2021 | +33,548 | Add 13.88% | 275,217 | $9.74 |
| Q2 2021 | +241,669 | New Buy | 241,669 | $9.90 |
| Q4 2018 | -23,600 | Sold Out | 0 | $0.00 |
| Q3 2018 | +2,400 | Add 11.32% | 23,600 | $21.53 |
| Q1 2018 | -6,500 | Reduce 23.47% | 21,200 | $17.08 |
| Q2 2017 | +3,000 | Add 12.15% | 27,700 | $33.21 |
| Q1 2016 | +600 | Add 2.49% | 24,700 | $53.52 |
| Q4 2015 | +24,100 | New Buy | 24,100 | $65.64 |
Ray Dalio's Teva Pharmaceutical Industries Limited Investment FAQs
Ray Dalio first purchased Teva Pharmaceutical Industries Limited (TEVA) in Q4 2015, acquiring 24,100 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Ray Dalio has held Teva Pharmaceutical Industries Limited (TEVA) for 32 quarters since Q4 2015.
Ray Dalio's largest addition to Teva Pharmaceutical Industries Limited (TEVA) was in Q3 2025, adding 864,782 shares worth $17.47 M.
According to the latest 13F filing for Q1 2026, Ray Dalio's firm, Bridgewater Associates, Lp, owns 1,128,406 shares of Teva Pharmaceutical Industries Limited (TEVA), valued at approximately $33.99 M.
As of the Q1 2026 filing, Teva Pharmaceutical Industries Limited (TEVA) represents approximately 0.15% of Ray Dalio's publicly disclosed stock portfolio, making it one of their key holdings.
Ray Dalio's peak holding in Teva Pharmaceutical Industries Limited (TEVA) was 1,128,406 shares, as reported at the end of Q1 2026.